Gene therapy approaches to sensitization of human prostate carcinoma to cisplatin by adenoviral expression of p53 and by antisense jun kinase oligonucleotide methods.
Gjerset
R
R
Sidney Kimmel Cancer Center, San Diego, CA, USA.
Haghighi
A
A
Lebedeva
S
S
Mercola
D
D
D000260:Adenoviruses, Human; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002945:Cisplatin / Q000494:pharmacology*; D015870:Gene Expression; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases; D008297:Male; D020928:Mitogen-Activated Protein Kinases / Q000235:genetics*; D016376:Oligonucleotides, Antisense; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000628:therapy*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D000970:Antineoplastic Agents; D016376:Oligonucleotides, Antisense; D016159:Tumor Suppressor Protein p53; D048031:JNK Mitogen-Activated Protein Kinases; D020928:Mitogen-Activated Protein Kinases; D002945:Cisplatin